Mood - Anxiety Disorders & Antidepressants – Mood Stabilizers

 (Haga un click en la información del journal para acceder al resúmen)

5 – doble-ciego o metanálisis; 4 – subanálisis o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión

 

3 - Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action

Catherine J. Harmer, Guy M. Goodwin, and Philip J. Cowen

The British Journal of Psychiatry (2009) 195: 102-108

 

3!! - Levels of anxiety and depression as predictors of mortality: the HUNT study

Arnstein Mykletun, Ottar Bjerkeset, Simon Øverland, Martin Prince, Michael Dewey, and Robert Stewart

The British Journal of Psychiatry (2009) 195: 118-125

 

5 - A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression. The Study of Pharmacotherapy of Psychotic Depression (STOP-PD)

Barnett S. Meyers, Alastair J. Flint, Anthony J. Rothschild, Benoit H. Mulsant, Ellen M. Whyte, Catherine Peasley-Miklus, Eros Papademetriou, Andrew C. Leon, Moonseong Heo, for the STOP-PD Group

Arch Gen Psychiatry. 2009;66(8):838-847

 

3! - Major Depression and Coronary Artery Disease in the Swedish Twin Registry. Phenotypic, Genetic, and Environmental Sources of Comorbidity

Kenneth S. Kendler, Charles O. Gardner, Amy Fiske, Margaret Gatz

Arch Gen Psychiatry. 2009;66(8):857-863

 

3! - National Patterns in Antidepressant Medication Treatment

Mark Olfson, Steven C. Marcus

Arch Gen Psychiatry. 2009;66(8):848-856

 

3! - Preschool Depression. Homotypic Continuity and Course Over 24 Months

Joan L. Luby, Xuemei Si, Andy C. Belden, Mini Tandon, Ed Spitznagel

Arch Gen Psychiatry. 2009;66(8):897-905

 

3 - Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients

Reiji Yoshimura, Wakako Umene-Nakano, Akihito Suzuki, Nobuhisa Ueda, Kyoko Miyamoto, Atsuko Ikenouchi-Sugita, Hikaru Hori, Koichi Otani, Jun Nakamura

Human Psychopharmacology: Clinical and Experimental. Volume 24 Issue 6, Pages 489 - 494

 

3 - Atypical depression: retrospective self-reporting of treatment effectiveness

G. Parker, J. Crawford

Acta Psychiatrica Scandinavica. Volume 120 Issue 3, Pages 213 - 221

 

3 - Lux vs. wavelength in light treatment of Seasonal Affective Disorder

J. L. Anderson , C. A. Glod, J. Dai, Y. Cao, S. W. Lockley

Acta Psychiatrica Scandinavica. Volume 120 Issue 3, Pages 203 - 212

 

3! - Early adversity in chronic depression: clinical correlates and response to pharmacotherapy

Daniel N. Klein, Bruce A. Arnow, Jennifer L. Barkin, Frank Dowling, James H. Kocsis, Andrew C. Leon, Rachel Manber, Barbara O. Rothbaum, Madhukar H. Trivedi, Stephen R. Wisniewski

Depression and Anxiety. Volume 26 Issue 8, Pages 701 - 710

 

3 - Abnormal neuroendocrine response to clomipramine in hereditary affective psychosis

Joachim Cordes, Rolf Larisch, Uwe Henning, Johanna Thünker, Christian Werner, Guillermo Orozco, Fermín Mayoral, Fabio Rivas, Georg Auburger, Marco Tosch, Marcella Rietschel, Wolfgang Gaebel, Hans-Wilhelm Müller, Ansgar Klimke

Depression and Anxiety. Volume 26 Issue 8, Pages E111 - E119

 

3! - Childhood neglect and abuse as predictors of antidepressant response in adult depression

Jeanette M. Johnstone, Suzanne E. Luty, Janet D. Carter, Roger T. Mulder, Christopher M.A. Frampton, Peter R. Joyce

Depression and Anxiety. Volume 26 Issue 8, Pages 711 - 717

 

3 - Chronic and acute stress and the prediction of major depression in women

Constance Hammen, Eunice Y. Kim, Nicole K. Eberhart, Patricia A. Brennan

Depression and Anxiety. Volume 26 Issue 8, Pages 718 - 723

 

3! - Obsessive–compulsive disorder: subclassification based on co-morbidity

G. Nestadt, C. Z. Di, M. A. Riddle, M. A. Grados, B. D. Greenberg, A. J. Fyer, J. T. McCracken, S. L. Rauch, D. L. Murphy, S. A. Rasmussen, B. Cullen, A. Pinto, J. A. Knowles, J. Piacentini, D. L. Pauls, O. J. Bienvenu, Y. Wang, K. Y. Liang, J. F. Samuels and K. Bandeen Roche

Psychological Medicine (2009), 39:1491-1501

 

3! - Valproate and neuroprotective effects for bipolar disorder

Murad Atmaca

International Review of Psychiatry, Volume 21, Issue 4 August 2009, pages 410 - 413

 

3 - Lithium and valproate and their possible effects on the myo -inositol second messenger system in healthy volunteers and bipolar patients

Peter H. Silverstone; Brent M. McGrath

International Review of Psychiatry, Volume 21, Issue 4 August 2009, pages 414 - 423

 

3 - More Lateral and Anterior Prefrontal Coil Location Is Associated with Better Repetitive Transcranial Magnetic Stimulation Antidepressant Response

Tal Herbsman, David Avery, Dave Ramsey, Paul Holtzheimer, Chandra Wadjik, Frances Hardaway, David Haynor, Mark S. George and Ziad Nahas

Biological Psychiatry. Volume 66, Issue 5, 1 September 2009, Pages 509-515

3 - Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data

William Victor Bobo & Richard C Shelton‌

Expert Opinion on Pharmacotherapy. September 2009, Vol. 10, No. 13, Pages 2145-2159

 

3 - Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants

Sonja Kwadijk-de Gijsel, Monique J. Bijl, Loes E. Visser, Ron H. N. van Schaik, Albert Hofman, Arnold G. Vulto, Teun van Gelder & Bruno H. Ch. Stricker

British Journal of Clinical Pharmacology. Volume 68 Issue 2, Pages 221 - 225

 

3! - Major Depression Is a Risk Factor for Low Bone Mineral Density: A Meta-Analysis

Raz Yirmiya and Itai Bab

Biological Psychiatry. Volume 66, Issue 5, 1 September 2009, Pages 423-432

3! - Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life

Katja Beesdo, Michael Höfler, Ellen Leibenluft, Roselind Lieb, Michael Bauer and Andrea Pfennig

Bipolar Disorders. Volume 11 Issue 6, Pages 637 - 649

 

3! - Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States

Benjamin I Goldstein, Andrea Fagiolini, Patricia Houck and David J Kupfer

Bipolar Disorders. Volume 11 Issue 6, Pages 657 - 662

 

3 - Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

Serretti, Alessandro; Calati, Raffaella; Massat, Isabelle; Linotte, Sylvie; Kasper, Siegfried; Lecrubier, Yves; Sens-Espel, Roser; Bollen, Joseph; Zohar, Joseph; Berlo, Jacques; Lienard, Patricia; De Ronchi, Diana; Mendlewicz, Julien; Souery, Daniel

International Clinical Psychopharmacology: September 2009 - Volume 24 - Issue 5 - pp 250-256

 

3< - Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study

Pessina, Enrico; Albert, Umberto; Bogetto, Filippo; Maina, Giuseppe

International Clinical Psychopharmacology: September 2009 - Volume 24 - Issue 5 - pp 265-269

 

3 - Antidepressant Medication Use During Breastfeeding

LANZA DI SCALEA, TERESA; WISNER, KATHERINE L

Clinical Obstetrics and Gynecology: September 2009 - Volume 52 - Issue 3 - pp 483-497

 

3 - Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder

Stephen R. Wisniewski, Chi-Chang Chen, Edward Kim, Hong J. Kan, Zhenchao Guo, Berit X. Carlson, Quynh-Van Tran, Andrei Pikalov

Pharmacoepidemiology and Drug Safety. Published Online: 6 Aug 2009

 

GRATIS 5 - Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration

Marc Stone, Thomas Laughren, M Lisa Jones, Mark Levenson, P Chris Holland, Alice Hughes, Tarek A Hammad, Robert Temple, George Rochester

BMJ 2009;339:b2880

 

GRATIS 3! - Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications

Santiago G Moreno, Alex J Sutton, Erick H Turner, Keith R Abrams, Nicola J Cooper, Tom M Palmer, A E Ades

BMJ 2009;339:b2981

 

Keming Gao, David V Sheehan and Joseph R Calabrese

Expert Review of Neurotherapeutics. August 2009, Vol. 9, No. 8, Pages 1147-1158

 

3! - Transplacental transfer and metabolism of bupropion

Angela D. Earhart;  Svetlana Patrikeeva;  Xiaoming Wang;  Doaa Reda Abdelrahman;  Gary D. V. Hankins;  Mahmoud S. Ahmed; Tatiana Nanovskaya

The Journal of Maternal-Fetal & Neonatal Medicine. First Published on: 31 July 2009

 

3! - When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR^*D Study

Roy H Perlis, Amanda Patrick, Jordan W Smoller and Philip S Wang

Neuropsychopharmacology (2009) 34, 2227–2236

 

3! - Prevalence of anxiety disorders among elderly people

Yalçin Kirmizioglu, Orhan Dogan, Nesim Kugu, Gamze Akyüz

International Journal of Geriatric Psychiatry. Volume 24 Issue 9, Pages 1026 - 1033

 

3 - Neural markers of symptomatic improvement during antidepressant therapy in severe depression: subgenual cingulate and visual cortical responses to sad, but not happy, facial stimuli are correlated with changes in symptom score

P Keedwell, D Drapier, S Surguladze, V Giampietro, M Brammer, M Phillips

Journal of Psychopharmacology, Vol. 23, No. 7, 775-788 (2009)

5 - Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial

CK Martin, H Han, SD Anton, FL Greenway, SR Smith

Journal of Psychopharmacology, Vol. 23, No. 7, 814-825 (2009)

3! - Paroxetine-induced increase in LDL cholesterol levels

JM Le Melledo, K Mailo, N Lara, MC Abadia, L Gil, M Van Ameringen, G Baker, J Perez-Parada

Journal of Psychopharmacology, Vol. 23, No. 7, 826-830 (2009)

3 - Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression?

M Ebinger, C Sievers, D Ivan, HJ Schneider, GK Stalla

Journal of Psychopharmacology, Vol. 23, No. 7, 841-853 (2009)

3 - Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder

T Eller, V Vasar, J Shlik, E Maron

Journal of Psychopharmacology, Vol. 23, No. 7, 854-858 (2009)

4 - Mood Stabilization and Destabilization During Acute and Continuation Phase Treatment for Bipolar I Disorder With Lamotrigine or Placebo

Joseph F. Goldberg, Joseph R. Calabrese, Benjamin R. Saville, Mark A. Frye, Terence A. Ketter, Trisha Suppes, Robert M. Post, and Frederick K. Goodwin

J Clin Psychiatry. Online ahead of print: August 11, 2009

 

5 - Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

Guy M. Goodwin, Robin Emsley, Sandra Rembry, and Frédéric Rouillon, for the Agomelatine Study Group

J Clin Psychiatry. Online ahead of print: August 11, 2009

 

3! - The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence

Mei Sheng Duh, Kevin E Cahill‌, Pierre Emmanuel Paradis‌, Pierre Y Cremieux & Paul E Greenberg

Expert Opinion on Pharmacotherapy. Posted online on 10 Aug 2009.

 

5 - Duloxetine for the Treatment of Recurrent Major Depressive Disorder in Elderly Patients: Treatment Outcomes in Patients With Comorbid Arthritis

Madelaine M. Wohlreich, Mark D. Sullivan, Craig H. Mallinckrodt, Amy S. Chappell, Tina M. Oakes, John G. Watkin, and Joel Raskin

Psychosomatics 50:402-412, July-August 2009

 

3! - The impact of age at onset of bipolar I disorder on functioning and clinical presentation

Frances Biffin, Steven Tahtalian, Kate Filia, Paul B. Fitzgerald, Anthony R. de Castella, Sacha Filia, Michael Berk, Seetal Dodd, Pam Callaly, Lesley Berk, Katarina Kelin, Meg Smith, William Montgomery, Jayashri Kulkarni

Acta Neuropsychiatrica. Volume 21 Issue 4, Pages 191 - 196

 

3! - Prevalence and Heritability of Compulsive Hoarding: A Twin Study

Alessandra C. Iervolino, Nader Perroud, Miguel Angel Fullana, Michel Guipponi, Lynn Cherkas, David A. Collier, and David Mataix-Cols

Am J Psychiatry Published August 17, 2009

 

5 - Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials

J. Craig Nelson, and George I. Papakostas

Am J Psychiatry Published August 17, 2009

GRATIS 3 - Effect of milnacipran on suicidality in patients with mild to moderate depressive disorder

Alla Avedisova, Vladimir Borodin, Ksenia Zakharova, et al

Neuropsychiatric Disease and Treatment. July 2009

 

3! - Effects of Lithium on Cognitive Performance: A Meta-Analysis

Aliza P. Wingo, Thomas S. Wingo, Philip D. Harvey, and Ross J. Baldessarini

J Clin Psychiatry. Online ahead of print: August 11, 2009

 

3 - [¹¹C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging

Donald F. Smith, Bo S. Stork, Gregers Wegener, Mahmoud Ashkanian, Steen Jakobsen, Dirk Bender, Hélène Audrain, Karina H. Vase, Søren B. Hansen, Poul Videbech and Raben Rosenberg

Psychopharmacology. Volume 206, Number 1 / September, 2009: 133-140

 

5 - Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity

Andreas B. Schmitt, Michael Bauer, Hans-Peter Volz, Hans-Jürgen Moeller, Qin Jiang, Philip T. Ninan and Peter-Andreas Loeschmann

European Archives of Psychiatry and Clinical Neuroscience. Volume 259, Number 6 / September, 2009: 329-339

 

3 - Implementation of CYP2D6 genotyping in psychiatry

Harriët M Loovers, Jan van der Weide

Expert Opinion on Drug Metabolism & Toxicology. September 2009, Vol. 5, No. 9, Pages 1065-1077

 

3 - Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

Paschos, Konstantinos A.; Veletza, Stavroula; Chatzaki, Ekaterini

CNS Drugs: 1 September 2009 - Volume 23 - Issue 9 - pp 755-772

 

3 - A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy

A. Verrotti, S. Agostinelli, G. Coppola, P. Parisi and F. Chiarelli

European Journal of Neurology. Published Online: 13 Aug 2009

 

3 - Ageing abolishes the effects of fluoxetine on neurogenesis

S Couillard-Despres, C Wuertinger, M Kandasamy, M Caioni, K Stadler, R Aigner, U Bogdahn and L Aigner

Molecular Psychiatry (2009) 14, 856–864

 

3 - Prevalence and correlates of obsessive–compulsive disorder among older adults living in the community

Sébastien Grenier, Michel Préville, Richard Boyer, Kieron O’Connor and Scientific Committee of the ESA Study

Journal of Anxiety Disorders. Volume 23, Issue 7, October 2009, Pages 858-865

 

3! - Prevalence of Mood, Anxiety, and Substance-Abuse Disorders for Older Americans in the National Comorbidity Survey-Replication

Gum, Amber M; King-Kallimanis, Bellinda; Kohn, Robert

American Journal of Geriatric Psychiatry: September 2009 - Volume 17 - Issue 9 - pp 769-781

 

3! - Comorbidity of Depressive and Anxiety Disorders for Older Americans in the National Comorbidity Survey-Replication

King-Kallimanis, Bellinda; Gum, Amber M; Kohn, Robert

American Journal of Geriatric Psychiatry: September 2009 - Volume 17 - Issue 9 - pp 782-792

 

3! - Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review

Marco Tuccori, Arianna Testi, Luca Antonioli, Matteo Fornai, Sabrina Montagnani, Narcisa Ghisu, Rocchina Colucci, Tiberio Corona, Corrado Blandizzi and Mario Del Tacca

Clinical Therapeutics. Volume 31, Part 1, 2009, Pages 1426-1453

3 - Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder

Richard Perry and Manouchkathe Cassagnol

Clinical Therapeutics. Volume 31, Part 1, 2009, Pages 1374-1404

5 - Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

Karen A. Touria, S. Krishna Padmanabhan, James Groark, Claudine Brisard and Deborah Farrington

Clinical Therapeutics. Volume 31, Part 1, 2009, Pages 1405-1423

3 - Disruption of the Circadian Timing Systems: Molecular Mechanisms in Mood Disorders

Mendlewicz, Julien

CNS Drugs: 1 September 2009 - Volume 23 - Issue - pp 15-26

 

3 - Agomelatine: Innovative Pharmacological Approach in Depression

Popoli, Maurizio

CNS Drugs: 1 September 2009 - Volume 23 - Issue - pp 27-34

 

3 - Agomelatine: Efficacy at Each Phase of Antidepressant Treatment

Kennedy, Sidney H

CNS Drugs: 1 September 2009 - Volume 23 - Issue - pp 41-47

 

3! - TPH2 polymorphisms may modify clinical picture in treatment-resistant depression

Sami Anttila, Merja Viikki, Kaija Huuhka, Martti Huuhka, Heini Huhtala, Riikka Rontu, Terho Lehtimäki and Esa Leinonen

Neuroscience Letters. Volume 464, Issue 1, 16 October 2009, Pages 43-46

 

3 - Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects

Masaki Kato, Gaku Okugawa, Masataka Wakeno, Yoshiteru Takekita, Shinpei Nonen, Shinji Tetsuo, Keiichiro Nishida, Junichi Azuma, Toshihiko Kinoshita and Alessandro Serretti

European Neuropsychopharmacology. Volume 19, Issue 10, October 2009, Pages 718-725

 

GRATIS 3 - Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder

Glenda M. MacQueen

J Psychiatry Neurosci 2009;34(5):343-9

 

3 - Short-term antidepressant treatment modulates amygdala response to happy faces

Ray Norbury, Matthew J. Taylor, Sudhakar Selvaraj, Susannah E. Murphy, Catherine J. Harmer and Philip J. Cowen

Psychopharmacology. Volume 206, Number 2 / October, 2009: 197-204

 

3! - Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder

Olga Chernoloz, Mostafa El Mansari and Pierre Blier

Psychopharmacology. Volume 206, Number 2 / October, 2009: 335-344

 

GRATIS (previo registro) 3 - Tratamiento con venlafaxina clorhidrato de mujeres climatéricas con diagnóstico de ansiedad o depresión. Estudio abierto

C. Iglesias,  E. Pato,  S. Ocio,  J. C. Ortigosa,  S. Santamarina,  M. J. Merino,  M. J. Alonso,  L. Fernández,  J. L. Alonso y L. Rodríguez

Actas Esp Psiquiatr 2009;37(3):137-142

 

GRATIS (previo registro) 3 - Eficacia y seguridad de risperidona inyectable de larga duración en fase de mantenimiento del trastorno bipolar y esquizoafectivo 
A. Benabarre, P. Castro, J. Sánchez-Moreno, A. Martínez-Arán, M. Salamero, A. Murru, C. Franco y E. Vieta

Actas Esp Psiquiatr 2009;37(3):143-147

 

GRATIS 3 - A Case–Control Study of Bipolar Depression, Compared With Unipolar Depression, in a Regional Hospital in Hong Kong

Wong Sze-man, Dunn Lai-wah, Tang Wai-nang, Chan Wah-fat, Chong Shiu-yin

Can J Psychiatry. 2009;54(7):452–459

 

3 - A Review of Modern Antidepressants’ Effects on Neurocognitive Function 
Eva Biringer, Arvid Rongve and Anders Lund

Current Psychiatry Reviews. Volume 5, Number 3, August 2009

 

3! - Bifrontal ECT: A Systematic Review and Meta-Analysis of Efficacy and Cognitive Impact
Chris Plakiotis and Daniel W. O'Connor

Current Psychiatry Reviews. Volume 5, Number 3, August 2009

 

GRATIS 1 - Cellular Abnormalities and EEG: Predicting Treatment Response in Depression

Dan V. Iosifescu

Psychiatry Weekly, Volume 4, Issue 18, on August 17, 2009

 

Gratis 3 - Treatment-Resistant Depression -- Part III: Switching Antidepressants vs. Conventional Augmentation Strategies

George I. Papakostas
Psychiatry Weekly, April 27, 2009

 

4 - Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study

Anthony J. Rothschild, Boadie W. Dunlop, David L. Dunner, Edward S. Friedman, Alan Gelenberg, Peter Holland, James H. Kocsis, Susan G. Kornstein, Richard Shelton, Madhukar H.

Trivedi, John M. Zajecka, Corey Goldstein, Michael E. Thase, Ron Pedersen, Martin B. Keller

Psychopharmacology Bulletin. 2009;42(3):00–00

 

4 - Analysis of Depressive Symptoms in Patients With Major Depressive Disorder Treated With Desvenlafaxine or Placebo

Susan G. Kornstein, Maurizio Fava, Qin Jiang, Karen A.Tourian

Psychopharmacology Bulletin. 2009;42(3):00–00

 

5 - Efficacy of Omega-3 Fatty Acids in Mood Disorders – A Systematic Review and Metaanalysis

Nina V. Kraguljac,Victor M. Montori, Mani Pavuluri, High S. Chai, Brian S.Wilson, Sencan S. Unal

Psychopharmacology Bulletin. 2009;42(3):00–00

 

3! - A Systematic Review of Augmentation Strategies for Patients With Major Depressive Disorder

Rachael Fleurence, Rebecca Williamson, Yonghua Jing, Edward Kim, Quynh-Van Tran, Andrei Pikalov, Michael E. Thase

Psychopharmacology Bulletin. 2009;42(3):00–00

 

3 - Anticonvulsants in the Treatment of Major Depressive Disorder: An Overview

Daniel V. Vigo; Ross J. Baldessarini

Harvard Review of Psychiatry, Volume 17, Issue 4 August 2009, pages 231 - 241

 

.

Regresar a RESÚMENES AGOSTO 2009